

Author Index

- Achiwa, K.: *See* Shimizu, T., 110
Ackerman, N.: *See* Bloom, N.D., 121
Agah, R.: *See* Hu, E., 96
Ahmad, A. and Law, K.: Recombinant targeted proteins for biotherapy, 67
Angenend, J.L.: *See* Hutchinson, V.A., 160, 217
Atzpodien, J.: *See* Kirchner, H., 145
Atzpodien, J., Körfer, A., Evers, P., Franks, C.R., Knüver-Hopf, J., Lopez-Hänninen, E., Fischer, M., Mohr, H., Dallmann, I., Hadam, M., Poliwođa, H. and Kirchner, H.: Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: A phase II outpatient study, 18
Azuma, I.: *See* Nishimura, K., 115
- Bennek, J.A.: *See* Vosika, G.J., 50
Bloom, N.D., Norbergs, D.A., Sherman, B., Sadjadi, M., Ramaswamy, G., Jacobs, R. and Ackerman, N.: Augmentation of the effect of doxorubicin with low-dose tumor necrosis factor in experimental liver metastasis, 121
Bocci, V., Carraro, F., Naldini, A., Cagol, P.P., Pasqual, E.M., Prevaldi, C. and Casara, D.: Distribution of human recombinant interferon- α 2 in rat plasma, liver, and experimental liver metastases, 233
Boosalis, M.G.: *See* Hu, E., 96
Braf, Z.: *See* Merimsky, O., 155
Bühring, H.J.: *See* Pawelec, G., 44
- Cagol, P.P.: *See* Bocci, V., 233
Carraro, F.: *See* Bocci, V., 233
Casara, D.: *See* Bocci, V., 233
Chaitchik, S.: *See* Merimsky, O., 155, 208
Chakrabarty, S., Mustain, S. and Wilson, J.K.V.: Induction of carcinoembryonic antigen and its crossreaction gene products in human colonic adenomas and carcinomas by transforming growth factor-beta, 27
Chen, S.C.: *See* Hu, E., 96
Chu, T.M.: *See* Nakajima, I., 228
Colin, C.: *See* Favrot, M.C., 32
Combaret, V.: *See* Favrot, M.C., 32
Cornelius, D.A.: *See* Vosika, G.J., 50
Coze, C.: *See* Favrot, M.C., 32
Cummins, J.M.: *See* Hutchinson, V.A., 160, 217, Koech, D.K., 91; Lecce, J.G., 211
- Dallmann, I.: *See* Atzpodien, J., 18
Del Rio, M.: *See* Stoudemire, J.B., 179
De Riese, W.: *See* Kirchner, H., 145
Dillman, R.O.: Rationales for combining chemotherapy and biotherapy in the treatment of cancer, 201
Doyle, L.A., Hamburger, A.W., Goldstein, L.H. and Park, H.-J.: Interaction of recombinant human tumor necrosis factor and etoposide in human lung cancer cell lines, 169
- Ehninger, G.: *See* Pawelec, G., 44
Evers, P.: *See* Atzpodien, J., 18; Kirchner, H., 145
- Faulk, W.P., Taylor, C.G., Yeh, C.-J.G. and McIntyre, J.A.: Preliminary clinical study of transferrin-Adriamycin conjugate for drug delivery to acute leukemia patients, 57
Favrot, M.C., Coze, C., Combaret, V., Gaspard, M., Colin, C., Franks, C.R., Negrier, S., Philip, I. and Philip, T.: Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: Optimization of the culture technique, 32
Fischer, M.: *See* Atzpodien, J., 18
Foxall, C.: *See* Mischak, R.P., 104; Stoudemire, J.B., 179
Franks, C.R.: *See* Atzpodien, J., 18; Favrot, M.C., 32; Kirchner, H., 145
- Gaspard, M.: *See* Favrot, M.C., 32
Gilbert, C.W.: *See* Vosika, G.J., 50
Goldmann, U.: *See* Kirchner, H., 145
Goldstein, L.H.: *See* Doyle, L.A., 169
Groshen, S.: *See* Hu, E., 96
- Hadam, M.: *See* Atzpodien, J., 18; Kirchner, H., 145
Hamburger, A.W.: *See* Doyle, L.A., 169
Harkonen, W.S.: *See* Stoudemire, J.B., 179
Hosokawa, M.: *See* Kawata, A., 221
House, R.V., Pearson, F.C. and Thomas, P.T.: Selective potentiation of host resistance in mice following treatment with Pyrexol, 175
Hu, E., Watkins, K., Groshen, S., Chen, S.C., Malloy, B., Agah, R., Nichols, P., Parker, J., Martin, A., Boosalis, M.G. and Mazumder, A.: Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies, 96
Hutchinson, V.A.: *See* Koech, D.K., 91
Hutchinson, V.A., Angenend, J.L., Mok, W.L., Cummins, J.M. and Richards, A.B.: Chronic recurrent aphthous stomatitis: oral treatment with low-dose interferon alpha, 160
Hutchinson, V.A., Mok, W.L.-L., Angenend, J.L., Cummins, J.M. and Richards, A.B.: Chronic major aphthous stomatitis: oral treatment with low-dose α -interferon, 217
- Inbar, M.: *See* Merimsky, O., 155, 208
Ito, K.: *See* Kawata, A., 221
Itoh, H.: *See* Shimizu, T., 110
- Jacobs, R.: *See* Bloom, N.D., 121
James, G.T.: *See* Mulvin, D.W., 38
Johnston, M.R.: *See* Mulvin, D.W., 38
- Kawata, A., Hosokawa, M., Sawamura, Y., Ito, K., Une, Y., Shibata, T., Uchino, J. and Kobayashi, H.: Modification of lymphokine-activated killer cell accumulation into tumor sites by chemotherapy, local irradiation, or splenectomy, 221
Khokhar, A.R.: *See* Nishikawa, K., 235
Kirchner, H.: *See* Atzpodien, J., 18
Kirchner, H., Körfer, A., Palmer, P.A., Evers, P., De Riese, W., Knüver-Hopf, J., Hadam, M., Goldmann, U., Franks, C.R., Poliwođa, H. and Atzpodien, J.: Subcutaneous interleukin-2 and interferon- α 2b in patients with metastatic renal cell cancer: the German outpatient experience, 145
Knebel, K.: *See* Mischak, R.P., 104
Knüver-Hopf, J.: *See* Atzpodien, J., 18; Kirchner, H., 145
Kobayashi, H.: *See* Kawata, A., 221
Koech, D.K., Obel, A.O., Minowada, J., Hutchinson, V.A., and Cummins, J.M.: Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1), 91
Körfer, A.: *See* Atzpodien, J., 18; Kirchner, H., 145
Kovner, F.: *See* Merimsky, O., 155
Kramer, B.S.: The consumer's risk in clinical trials, 132
Kruse, C.A.: *See* Mulvin, D.W., 38
- Laufer, R.: *See* Merimsky, O., 155
Law, K.: *See* Ahmad, A., 67
Lecce, J.G., Cummins, J.M. and Richards, A.B.: Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha, 211
Lentz, M.R.: The phylogeny of oncology, 137
Lenz, H.: *See* Pawelec, G., 44
Lopez-Hänninen, E.: *See* Atzpodien, J., 18
- Malloy, B.: *See* Hu, E., 96
Marcell, T.: *See* Mulvin, D.W., 38
Martin, A.: *See* Hu, E., 96
Masuzawa, T.: *See* Shimizu, T., 110
Mazumder, A.: *See* Hu, E., 96
McIntyre, J.A.: *See* Faulk, W.P., 57
Merimsky, O.: *See* Merimsky, O., 155
Merimsky, O., Inbar, M., Merimsky, E., Kovner, F., Spitzer, E., Laufer, R., Braf, Z. and Chaitchik, S.: Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma, 155
Merimsky, O., Inbar, M., Shiloni, E., Ron, I. and Chaitchik, S.: Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by α -interferon and dacarbazine—a preliminary report, 208
Miklavčić, D.: *See* Serša, G., 165
Minowada, J.: *See* Koech, D.K., 91
Mischak, R.: *See* Stoudemire, J.B., 179
Mischak, R.P., Foxall, C., Rosendorf, L.L., Knebel, K., Scannon, P.J. and Spitler, L.E.: Human antibody responses to components of the monoclonal antimeelanoma antibody ricin A chain immunotoxin Xoma Zyme-MEL, 104
Mitchell, D.H.: *See* Mulvin, D.W., 38
Mohr, H.: *See* Atzpodien, J., 18
Mok, W.L.-L.: *See* Hutchinson, V.A., 160, 217
Mulvin, D.W., Kruse, C.A., Mitchell, D.H., Marcell, T., James, G.T., Johnston, M.R.: Lymphokine-activated killer cells with interleukin-2: Dose

Author Index

- Achiwa, K.: *See* Shimizu, T., 110
Ackerman, N.: *See* Bloom, N.D., 121
Agah, R.: *See* Hu, E., 96
Ahmad, A. and Law, K.: Recombinant targeted proteins for biotherapy, 67
Angenend, J.L.: *See* Hutchinson, V.A., 160, 217
Atzpodien, J.: *See* Kirchner, H., 145
Atzpodien, J., Körfer, A., Evers, P., Franks, C.R., Knüver-Hopf, J., Lopez-Hänninen, E., Fischer, M., Mohr, H., Dallmann, I., Hadam, M., Poliwođa, H. and Kirchner, H.: Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: A phase II outpatient study, 18
Azuma, I.: *See* Nishimura, K., 115
- Bennek, J.A.: *See* Vosika, G.J., 50
Bloom, N.D., Norbergs, D.A., Sherman, B., Sadjadi, M., Ramaswamy, G., Jacobs, R. and Ackerman, N.: Augmentation of the effect of doxorubicin with low-dose tumor necrosis factor in experimental liver metastasis, 121
Bocci, V., Carraro, F., Naldini, A., Cagol, P.P., Pasqual, E.M., Prevaldi, C. and Casara, D.: Distribution of human recombinant interferon- α 2 in rat plasma, liver, and experimental liver metastases, 233
Boosalis, M.G.: *See* Hu, E., 96
Braf, Z.: *See* Merimsky, O., 155
Bühring, H.J.: *See* Pawelec, G., 44
- Cagol, P.P.: *See* Bocci, V., 233
Carraro, F.: *See* Bocci, V., 233
Casara, D.: *See* Bocci, V., 233
Chaitchik, S.: *See* Merimsky, O., 155, 208
Chakrabarty, S., Mustain, S. and Wilson, J.K.V.: Induction of carcinoembryonic antigen and its crossreaction gene products in human colonic adenomas and carcinomas by transforming growth factor-beta, 27
Chen, S.C.: *See* Hu, E., 96
Chu, T.M.: *See* Nakajima, I., 228
Colin, C.: *See* Favrot, M.C., 32
Combaret, V.: *See* Favrot, M.C., 32
Cornelius, D.A.: *See* Vosika, G.J., 50
Coze, C.: *See* Favrot, M.C., 32
Cummins, J.M.: *See* Hutchinson, V.A., 160, 217, Koech, D.K., 91; Lecce, J.G., 211
- Dallmann, I.: *See* Atzpodien, J., 18
Del Rio, M.: *See* Stoudemire, J.B., 179
De Riese, W.: *See* Kirchner, H., 145
Dillman, R.O.: Rationales for combining chemotherapy and biotherapy in the treatment of cancer, 201
Doyle, L.A., Hamburger, A.W., Goldstein, L.H. and Park, H.-J.: Interaction of recombinant human tumor necrosis factor and etoposide in human lung cancer cell lines, 169
- Ehninger, G.: *See* Pawelec, G., 44
Evers, P.: *See* Atzpodien, J., 18; Kirchner, H., 145
- Faulk, W.P., Taylor, C.G., Yeh, C.-J.G. and McIntyre, J.A.: Preliminary clinical study of transferrin-Adriamycin conjugate for drug delivery to acute leukemia patients, 57
Favrot, M.C., Coze, C., Combaret, V., Gaspard, M., Colin, C., Franks, C.R., Negrier, S., Philip, I. and Philip, T.: Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: Optimization of the culture technique, 32
Fischer, M.: *See* Atzpodien, J., 18
Foxall, C.: *See* Mischak, R.P., 104; Stoudemire, J.B., 179
Franks, C.R.: *See* Atzpodien, J., 18; Favrot, M.C., 32; Kirchner, H., 145
- Gaspard, M.: *See* Favrot, M.C., 32
Gilbert, C.W.: *See* Vosika, G.J., 50
Goldmann, U.: *See* Kirchner, H., 145
Goldstein, L.H.: *See* Doyle, L.A., 169
Groshen, S.: *See* Hu, E., 96
- Hadam, M.: *See* Atzpodien, J., 18; Kirchner, H., 145
Hamburger, A.W.: *See* Doyle, L.A., 169
Harkonen, W.S.: *See* Stoudemire, J.B., 179
Hosokawa, M.: *See* Kawata, A., 221
House, R.V., Pearson, F.C. and Thomas, P.T.: Selective potentiation of host resistance in mice following treatment with Pyrexol, 175
Hu, E., Watkins, K., Groshen, S., Chen, S.C., Malloy, B., Agah, R., Nichols, P., Parker, J., Martin, A., Boosalis, M.G. and Mazumder, A.: Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies, 96
Hutchinson, V.A.: *See* Koech, D.K., 91
Hutchinson, V.A., Angenend, J.L., Mok, W.L., Cummins, J.M. and Richards, A.B.: Chronic recurrent aphthous stomatitis: oral treatment with low-dose interferon alpha, 160
Hutchinson, V.A., Mok, W.L.-L., Angenend, J.L., Cummins, J.M. and Richards, A.B.: Chronic major aphthous stomatitis: oral treatment with low-dose α -interferon, 217
- Inbar, M.: *See* Merimsky, O., 155, 208
Ito, K.: *See* Kawata, A., 221
Itoh, H.: *See* Shimizu, T., 110
- Jacobs, R.: *See* Bloom, N.D., 121
James, G.T.: *See* Mulvin, D.W., 38
Johnston, M.R.: *See* Mulvin, D.W., 38
- Kawata, A., Hosokawa, M., Sawamura, Y., Ito, K., Une, Y., Shibata, T., Uchino, J. and Kobayashi, H.: Modification of lymphokine-activated killer cell accumulation into tumor sites by chemotherapy, local irradiation, or splenectomy, 221
Khokhar, A.R.: *See* Nishikawa, K., 235
Kirchner, H.: *See* Atzpodien, J., 18
Kirchner, H., Körfer, A., Palmer, P.A., Evers, P., De Riese, W., Knüver-Hopf, J., Hadam, M., Goldmann, U., Franks, C.R., Poliwođa, H. and Atzpodien, J.: Subcutaneous interleukin-2 and interferon- α 2b in patients with metastatic renal cell cancer: the German outpatient experience, 145
Knebel, K.: *See* Mischak, R.P., 104
Knüver-Hopf, J.: *See* Atzpodien, J., 18; Kirchner, H., 145
Kobayashi, H.: *See* Kawata, A., 221
Koech, D.K., Obel, A.O., Minowada, J., Hutchinson, V.A., and Cummins, J.M.: Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1), 91
Körfer, A.: *See* Atzpodien, J., 18; Kirchner, H., 145
Kovner, F.: *See* Merimsky, O., 155
Kramer, B.S.: The consumer's risk in clinical trials, 132
Kruse, C.A.: *See* Mulvin, D.W., 38
- Laufer, R.: *See* Merimsky, O., 155
Law, K.: *See* Ahmad, A., 67
Lecce, J.G., Cummins, J.M. and Richards, A.B.: Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha, 211
Lentz, M.R.: The phylogeny of oncology, 137
Lenz, H.: *See* Pawelec, G., 44
Lopez-Hänninen, E.: *See* Atzpodien, J., 18
- Malloy, B.: *See* Hu, E., 96
Marcell, T.: *See* Mulvin, D.W., 38
Martin, A.: *See* Hu, E., 96
Masuzawa, T.: *See* Shimizu, T., 110
Mazumder, A.: *See* Hu, E., 96
McIntyre, J.A.: *See* Faulk, W.P., 57
Merimsky, O.: *See* Merimsky, O., 155
Merimsky, O., Inbar, M., Merimsky, E., Kovner, F., Spitzer, E., Laufer, R., Braf, Z. and Chaitchik, S.: Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma, 155
Merimsky, O., Inbar, M., Shiloni, E., Ron, I. and Chaitchik, S.: Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by α -interferon and dacarbazine—a preliminary report, 208
Miklavčić, D.: *See* Serša, G., 165
Minowada, J.: *See* Koech, D.K., 91
Mischak, R.: *See* Stoudemire, J.B., 179
Mischak, R.P., Foxall, C., Rosendorf, L.L., Knebel, K., Scannon, P.J. and Spitler, L.E.: Human antibody responses to components of the monoclonal antimeelanoma antibody ricin A chain immunotoxin Xoma Zyme-MEL, 104
Mitchell, D.H.: *See* Mulvin, D.W., 38
Mohr, H.: *See* Atzpodien, J., 18
Mok, W.L.-L.: *See* Hutchinson, V.A., 160, 217
Mulvin, D.W., Kruse, C.A., Mitchell, D.H., Marcell, T., James, G.T., Johnston, M.R.: Lymphokine-activated killer cells with interleukin-2: Dose

- toxicity and localization in isolated perfused rat lungs, 38
Murray, L.: *See* Nishikawa, K., 235
Mustain, S.: *See* Chakrabarty, S., 27
- Nakajima, I. and Chu, T.M.: Prostaglandin E₂-mediated suppression of murine lymphokine-activated killer cell activity generated from tumor-bearing hosts by interferon- γ , 228
Nakamoto, S.-i.: *See* Shimizu, T., 110
Naldini, A.: *See* Bocci, V., 233
Negrier, S.: *See* Favrot, M.C., 32
Newman, R.A.: *See* Nishikawa, K., 235
Nichols, P.: *See* Hu, E., 96
Nishi, N.: *See* Nishimura, K., 115
Nishikawa, K., Newman, R.A., Murray, L., Khokhar, A.R. and Rosenblum, M.G.: Detection of cellular platinum using the monoclonal antibody IC1, 235
Nishimura, K., Nishimura, S.-i., Nishi, N., Tokura, S. and Azuma, I.: Effect of chitin heparinoids on the activation of peritoneal macrophages and on the production of monokines in mice, 115
Nishimura, S.-i.: *See* Nishimura, K., 115
Norbergs, D.A.: *See* Bloom, N.D., 121
- Obel, A.O.: *See* Koech, D.K., 91
Ohtsuka, Y.: *See* Shimizu, T., 110
Oldham, R.K.: Book Reviews, 185, 242, 243
Cancer and diabetes: Are there similarities?, 130
Cancer cures: By the people, for the people, at what cost?, 2
Research funding: a disclosure item, 66
Set my factors free, 194
Owsianowski, M.: *See* Pawelec, G., 44
- Palmer, P.A.: *See* Kirchner, H., 145
Park, H.-J.: *See* Doyle, L.A., 169
Parker, J.: *See* Hu, E., 96
Pasqual, E.M.: *See* Bocci, V., 233
- Pawelec, G., Schwuléra, U., Lenz, H., Owsianowski, M., Bühring, H.J., Schlag, H., Schneider, E., Schaudt, K. and Ehninger, G.: Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2, 44
Pearson, F.C.: *See* House, R.V., 175
Philip, I.: *See* Favrot, M.C., 32
Philip, T.: *See* Favrot, M.C., 32
Poliwoda, H.: *See* Atzpodien, J., 18;
Kirchner, H., 145
Prevaldi, C.: *See* Bocci, V., 233
- Ramaswamy, G.: *See* Bloom, N.D., 121
Richards, A.B.: *See* Hutchinson, V.A., 160, 217; Lecce, J.G., 211
Ron, I.: *See* Merimsky, O., 208
Rosenblum, M.G.: *See* Nishikawa, K., 235
Rosendorf, L.L.: *See* Mischak, R.P., 104
- Sadjadi, M.: *See* Bloom, N.D., 121
Sadlik, J.R.: *See* Vosika, G.J., 50
Sawamura, Y.: *See* Kawata, A., 221
Scannon, P.J.: *See* Mischak, R.P., 104
Schaudt, K.: *See* Pawelec, G., 44
Schlag, H.: *See* Pawelec, G., 44
Schneider, E.: *See* Pawelec, G., 44
Schwuléra, U.: *See* Pawelec, G., 44
Serša, G. and Miklavčič, D.: Inhibition of SA-1 tumor growth in mice by human leukocyte interferon alpha combined with low-level direct current, 165
Sherman, B.: *See* Bloom, N.D., 121
Shibata, T.: *See* Kawata, A., 221
Shiloni, E.: *See* Merimsky, O., 208
Shimizu, T., Ohtsuka, Y., Masuzawa, T., Yanagihara, Y., Itoh, H., Nakamoto, S.-i. and Achiwa, K.: Antitumor activity against Meth A fibrosarcoma and biologic activities of synthetic monosaccharide analogs of lipid A in mice, 110
- Spitler, L.E.: Book review, 125
activities of synthetic monosaccharide analogs of lipid A in mice, 110
See Mischak, R.P., 104; Stoudemire, J.B., 179
Spitzer, E.: *See* Merimsky, O., 155
Stoudemire, J.B., Mischak, R., Foxall, C., Harkonen, W.S., Del Rio, M. and Spitler, L.E.: The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats, 179
- Taylor, C.G.: *See* Faulk, W.P., 57
Thomas, P.T.: *See* House, R.V., 175
Tokura, S.: *See* Nishimura, K., 115
- Uchino, J.: *See* Kawata, A., 221
Une, Y.: *See* Kawata, A., 221
- Vosika, G.J., Cornelius, D.A., Bennek, J.A., Sadlik, J.R. and Gilbert, C.W.: Immunologic and toxicologic study of disaccharide tripeptide glycerol dipalmitoyl: A new lipophilic immunomodulator, 50
- Watkins, K.: *See* Hu, E., 96
Willson, J.K.V.: *See* Chakrabarty, S., 27
Wimer, B.M.: Characteristics of PHA-L4, the mitogenic isolectin of phytohemagglutinin, as an ideal biologic response modifier, 4
Potential therapeutic applications of PHA-L4, the mitogenic isolectin of phytohemagglutinin, 196
Therapeutic activities of PHA-L4, the mitogenic isolectin of phytohemagglutinin, 74
- Yanagihara, Y.: *See* Shimizu, T., 110
Yeh, C.-J.G.: *See* Faulk, W.P., 57

Subject Index

Acquired immunodeficiency syndrome, 196
 Acquired tolerance, 137
 Active and adoptive immunotherapy, 74
 Acute leukemia, 57
 Adoptive immunotherapy of cancer, 44
 Alloactivated killer and PHA-activated killer cell pathways, 74
 Allograft transplantation, 74, 196
 Antidiotype melanoma, 104
 Antitumor activity, 110
 Aphthous stomatitis, chronic, 160, 217
 Aplastic anemias, 196

Biologic response modifiers, 4, 74, 175
 Biotherapy, 67, 175

Cancer, 96
 Cancer immunotherapy, 196
 CD4⁺ lymphocyte, 91
 CEA, 27
 Cell cycle, 235
 Cellular localization, 235
 Cellular suppression, 44
 Chemotherapy, 221
 Chimeric antibodies, 67
 Chitin heparinoids, 115
 Clinical trial methodology, 132
 Colony-stimulating factor, 115
 Combining chemotherapy and biotherapy, 201
 Consumers' risk, 132
 Cyclophosphamide, 179

Diarrhea, 211
 Direct current, 165
 Disaccharide tripeptide, 50
 Doxorubicin, 121
 Drug targeting, 57

Etoposide, 169
 Evolutionary mechanism, 137
 Extensive burns, 196

Fetal tissue, 137

Gamma interferon, 96
 Granulocyte-macrophage colony-stimulating factor, 44

Hepatic metastasis, 121
 HIV-1, 91
 Host resistance, 175
 Human colonic adenomas and carcinomas, 27
 Human immunodeficiency virus infection, 196
 Human immunodeficiency virus type-1, 91

IL-2, 32
 Immunosuppression, 74, 179
 Immunotherapy, 32, 175
 Immunotoxin, 104, 179
¹¹¹In-oxine, 221
 Influenza, 175
 α -interferon, 208
 Interferon, 91, 217, 233
 Interferon alpha, 145, 160, 165, 211, 217, 233
 Interferon- γ , 44, 228
 Interleukin-1, 115
 Interleukin-2, 18, 38, 96, 145, 208, 228
 Interstitial fluid, 233
In vitro expansion, 32
 Irradiation, 221
 Isolated perfused rat lungs, 38

L4 isolectin, 4, 74, 196
 LAK accumulations, 221
 LAK cells, 32
 Lethal toxicity, 110
 Lipid A analogs, 110
 Listeriosis, 175
 Liver metastases, 233
 Lung cancer, 169
 Lymphokine-activated killer cells, 38, 228

Macrophage activation, 115
 Macrophages, 228
 Metastatic disease, 155

Metastatic malignant melanoma, 208
 MHC-unrestricted cytotoxicity, 44
 Mitogenic activity, 115
 Mitogenicity, 110
 Mitogenic lectins, 4, 74
 Monoclonal antibody, 235
 Monocyte activation, 50
 Mouse, 228
 Murine sarcoma, 165

Natural interleukin-2, 44
 Neoplastic tissue, 137

Phase 1, 96
 Phase II application study, 18
 Phytohemagglutinin, 4, 74, 196
 Phytohemagglutinin-activated killer (PAK) cells, 4
 Platinum compounds, 235
 Prostaglandin E₂, 228

Recombinant interferon alpha-C, 155
 Recombinant proteins, 67
 Renal cell carcinoma, 145, 155
 Ricin A chain, 104
 Rotavirus, 211

Subcutaneous application, 18
 Swine, 211

^{99m}Tc albumin, 233
 TGF-B, 27
 Therapy, 211
 Toxicity, 38
 Toxins, 67
 Transferrin-Adriamycin, 57
 Transferrin receptors, 57
 Tumor necrosis factor, 121, 169
 Tumor necrosis factor- α , 44
 Tumor treatment, 165
 Type-1 error, 132
 Type-2 error, 132

Vaccine adjuvant, 196

